Coronis: Creating Virtual Companies

Launched by four veterans of the medical device industry, Coronis Medical hopes to be able to nurture precisely the kind of opportunities that even the most early stage-minded of venture investors can't. Through its relationship with Stellartech, a design and development consulting firm, Coronis will be able to provide a wide array of services for the projects it takes on, creating virtual companies through what is, in effect, a kind of virtual incubator.

Because the technology risks of medical device development are so much lower than those of, say, biotech, most venture capital firms can afford to invest as early as possible. And since exits also tend to be smaller in devices, they have to--it’s only by investing early that investors capture the maximum value for their capital. But precisely because of those lower returns, investing too early can be a problem if the technology ultimately doesn’t pan out.

Would-be entrepreneurs therefore often find that VCs who preach the benefits of investing early generally turn a cold shoulder to...

More from Strategy

Avalyn Raises $100m Series D To Advance Inhaled Pulmonary Fibrosis Candidates

 
• By 

Looking to improve on the efficacy and safety of Roche’s Esbriet and BI’s Ofev, Avalyn has inhalable formulations of those drugs in Phase IIb and Phase I, respectively.

Replimune CRL Could Hold Warning For Accelerated Approvals

 

FDA issued a complete response letter to Replimune’s BLA for a novel oncolytic immunotherapy for melanoma in a surprise to management and investors.

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By 

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By 

The Austrian firm is delisting from the NASDAQ and closing down.

More from Business

Stock Watch: Q2 Sales Growth Sparks Diverging Reactions To J&J And Novartis

 
• By 

With drug sector indexes underperforming the broad market in the first half of 2025, investors may have been anticipating tariff-related and other headwinds. But impending loss of exclusivity on key products may be provoking more anxiety at this point.

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By 

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: J&J delivers in Q2 despite Stelara drop; Sarepta cuts jobs as Elevidys slumps; AI is inevitable but needs to be applied appropriately; China’s mid-cap companies thrive; and a look behind Glenmark’s landmark trispecific deal.